Lake Country Advisors

AUGUST 8, 2024

It’s integral to ensuring that the sale benefits all stakeholders and should be one of your priorities before advertising it to potential buyers. It’s a delicate balancing act, as inaccurate valuations have polarizing consequences. First, identify a group of similar publicly traded technology companies.

Valuation 97

Valuation Discounted Cash Flow S&P DCF Analysis 97

Software Equity Group

MARCH 13, 2023

The public markets may have taken a beating, but behind the gloom-and-doom headlines, there was still plenty of good news for private SaaS companies in 2022. On the surface, things looked rough: the Dow Jones, S&P 500, and the NASDAQ all finished the year with significant losses, with tech stocks hit particularly hard.

M&A 52

M&A Private Equity Equities S&P 52

Software Equity Group

MAY 7, 2024

Learn more about the external influences shaping your SaaS company’s valuation multiple below. #1. The most active verticals in 2023 were Healthcare, Financial Services, and Real Estate. It’s important to remember that no key metric exists in a vacuum. It’s partly a matter of perception.

M&A 52

M&A Valuation Economics Business 52

Software Equity Group

MAY 8, 2024

Learn more about the external influences shaping your SaaS company’s valuation multiple below. #1. The most active verticals in 2023 were Healthcare, Financial Services, and Real Estate. It’s important to remember that no key metric exists in a vacuum. It’s partly a matter of perception.

M&A 52

M&A Valuation Economics Business 52

Cooley M&A

JANUARY 20, 2022

While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. on transactions over 2019’s mega?mergers. General trends in life sciences M&A.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40